Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219,496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study.
Zeng YM, Li Y, Lu YQ, Liu M, Nie JM, Yuan J, Harypursat V, Zhou YH, Qin YY, Chen XH, Zhang YL, Zhang DF, Wang N, Chen H, Tian Q, Zhou Y, Qin YM, Yang XP, Chen YK. Zeng YM, et al. Among authors: li y. BMC Pulm Med. 2022 Aug 25;22(1):323. doi: 10.1186/s12890-022-02118-4. BMC Pulm Med. 2022. PMID: 36008855 Free PMC article.
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
Zeng YM, Xu XL, He XQ, Tang SQ, Li Y, Huang YQ, Harypursat V, Chen YK. Zeng YM, et al. Among authors: li y. Chin Med J (Engl). 2020 May 5;133(9):1132-1134. doi: 10.1097/CM9.0000000000000790. Chin Med J (Engl). 2020. PMID: 32149772 Free PMC article. No abstract available.
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis.
Zeng YM, Li Y, He XQ, Huang YQ, Liu M, Yuan J, Bai Y, Lu YQ, Li H, Chen YK. Zeng YM, et al. Among authors: li y, li h. Medicine (Baltimore). 2020 Jul 17;99(29):e21141. doi: 10.1097/MD.0000000000021141. Medicine (Baltimore). 2020. PMID: 32702867 Free PMC article. Clinical Trial.
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
Huang YQ, Tang SQ, Xu XL, Zeng YM, He XQ, Li Y, Harypursat V, Lu YQ, Wan Y, Zhang L, Sun QZ, Sun NN, Wang GX, Yang ZP, Chen YK. Huang YQ, et al. Among authors: li y. Front Pharmacol. 2020 Jul 14;11:1071. doi: 10.3389/fphar.2020.01071. eCollection 2020. Front Pharmacol. 2020. PMID: 32765274 Free PMC article.
219,496 results
You have reached the last available page of results. Please see the User Guide for more information.